🚀 VC round data is live in beta, check it out!
Schott Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Schott Pharma and similar public comparables like Shandong Weigao Blood, Inner Mongolia Furui Medical Science, Dentsply Sirona, Haemonetics and more.
Schott Pharma Overview
About Schott Pharma
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
Founded
1884
HQ
Employees
4.8K
Website
Sectors
Financials (LTM)
EV
$3B
Schott Pharma Financials
Schott Pharma reported last 12-month revenue of $1B and EBITDA of $322M.
In the same LTM period, Schott Pharma generated $390M in gross profit, $322M in EBITDA, and $168M in net income.
Revenue (LTM)
Schott Pharma P&L
In the most recent fiscal year, Schott Pharma reported revenue of $1B and EBITDA of $329M.
Schott Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $390M | XXX | $381M | XXX | XXX | XXX |
| Gross Margin | 34% | XXX | 33% | XXX | XXX | XXX |
| EBITDA | $322M | XXX | $329M | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $168M | XXX | $172M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 15% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Schott Pharma Stock Performance
Schott Pharma has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Schott Pharma's stock price is $16.67.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | -0.7% | XXX | XXX | XXX | $1.14 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSchott Pharma Valuation Multiples
Schott Pharma trades at 2.2x EV/Revenue multiple, and 8.0x EV/EBITDA.
EV / Revenue (LTM)
Schott Pharma Financial Valuation Multiples
As of March 20, 2026, Schott Pharma has market cap of $3B and EV of $3B.
Equity research analysts estimate Schott Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Schott Pharma has a P/E ratio of 15.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 8.0x | XXX | 7.8x | XXX | XXX | XXX |
| EV/EBIT | 11.4x | XXX | 11.0x | XXX | XXX | XXX |
| EV/Gross Profit | 6.6x | XXX | 6.8x | XXX | XXX | XXX |
| P/E | 15.0x | XXX | 14.6x | XXX | XXX | XXX |
| EV/FCF | 41.0x | XXX | 47.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Schott Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Schott Pharma Margins & Growth Rates
Schott Pharma's revenue in the last 12 month grew by 3%.
Schott Pharma's revenue per employee in the last FY averaged $0.2M.
Schott Pharma's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Schott Pharma's rule of X is 36% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Schott Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | (4%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 36% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 9% | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 14% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Schott Pharma Public Comps
See public comps and valuation multiples for other Medical Supplies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Shandong Weigao Blood | XXX | XXX | XXX | XXX | XXX | XXX |
| Inner Mongolia Furui Medical Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Dentsply Sirona | XXX | XXX | XXX | XXX | XXX | XXX |
| Haemonetics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Schott Pharma M&A Activity
Schott Pharma acquired XXX companies to date.
Last acquisition by Schott Pharma was on XXXXXXXX, XXXXX. Schott Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Schott Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSchott Pharma Investment Activity
Schott Pharma invested in XXX companies to date.
Schott Pharma made its latest investment on XXXXXXXX, XXXXX. Schott Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Schott Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Schott Pharma
| When was Schott Pharma founded? | Schott Pharma was founded in 1884. |
| Where is Schott Pharma headquartered? | Schott Pharma is headquartered in Germany. |
| How many employees does Schott Pharma have? | As of today, Schott Pharma has over 4K employees. |
| Is Schott Pharma publicly listed? | Yes, Schott Pharma is a public company listed on Frankfurt Stock Exchange. |
| What is the stock symbol of Schott Pharma? | Schott Pharma trades under 1SXP ticker. |
| When did Schott Pharma go public? | Schott Pharma went public in 2023. |
| Who are competitors of Schott Pharma? | Schott Pharma main competitors are Shandong Weigao Blood, Inner Mongolia Furui Medical Science, Dentsply Sirona, Haemonetics. |
| What is the current market cap of Schott Pharma? | Schott Pharma's current market cap is $3B. |
| What is the current revenue of Schott Pharma? | Schott Pharma's last 12 months revenue is $1B. |
| What is the current revenue growth of Schott Pharma? | Schott Pharma revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Schott Pharma? | Current revenue multiple of Schott Pharma is 2.2x. |
| Is Schott Pharma profitable? | Yes, Schott Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Schott Pharma? | Schott Pharma's last 12 months EBITDA is $322M. |
| What is Schott Pharma's EBITDA margin? | Schott Pharma's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Schott Pharma? | Current EBITDA multiple of Schott Pharma is 8.0x. |
| What is the current FCF of Schott Pharma? | Schott Pharma's last 12 months FCF is $63M. |
| What is Schott Pharma's FCF margin? | Schott Pharma's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Schott Pharma? | Current FCF multiple of Schott Pharma is 41.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.